Почетна › Беркитов лимфом › Њујорк

Клинички испитувања за Беркитов лимфом во Њујорк

20 студии за Беркитов лимфом бараат учесници на локации во Њујорк.

Градови во Њујорк

Официјален текст на студијата (англиски)

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

Albany Medical Center, Albany
Roswell Park Cancer Institute, Buffalo
NYU Langone Hospital - Long Island, Mineola
и уште 9

Се регрутираФаза 2

366 Days – 46 Years · Сите полови · Ажурирано 2.10.2026 · NCT06124157

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

Roswell Park Cancer Institute, Buffalo
Northwell Health/Center for Advanced Medicine, Lake Success
North Shore University Hospital, Manhasset
и уште 4

Се регрутираФаза 3

Возраст од 18 до 39 · Сите полови · Ажурирано 2.10.2026 · NCT03150693

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

Northwell Health/Center for Advanced Medicine, Lake Success
North Shore University Hospital, Manhasset
Long Island Jewish Medical Center, New Hyde Park
и уште 2

Се регрутираФаза 2

Возраст 18 и постари · Сите полови · Ажурирано 29.9.2026 · NCT03739814

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Albany Medical Center, Albany
Roswell Park Cancer Institute, Buffalo
The Steven and Alexandra Cohen Children's Medical Center of New York, New Hyde Park
и уште 7

Се регрутираФаза 2

365 Days · Сите полови · Ажурирано 25.9.2026 · NCT06317662

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

David H. Koch Center for Cancer Care, New York
Montefiore Medical Center PRIME, The Bronx

Се регрутираФаза 3

Возраст 18 и постари · Сите полови · Ажурирано 21.9.2026 · NCT07648264

A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia

Memorial Sloan Kettering Cancer Center, New York

Се регрутираФаза 3

Возраст 1 и постари · Сите полови · Ажурирано 17.9.2026 · NCT07223021

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

Memorial Sloan Kettering Cancer Center ( Site 1010), New York
New York Medical College ( Site 1023), Valhalla

Се регрутираФаза 1/2

6 Months – 25 Years · Сите полови · Ажурирано 17.9.2026 · NCT06395103

A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

The Mount Sinai Hospital, New York

Се регрутираФаза 1

Возраст од 0 до 18 · Сите полови · Ажурирано 16.9.2026 · NCT06173518

Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

Columbia University Irving Medical Center/New York Presbyterian Hospital, New York

Се регрутираФаза 1

Возраст 18 и постари · Сите полови · Ажурирано 8.9.2026 · NCT03666000

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Albany Medical Center, Albany
Maimonides Medical Center, Brooklyn
NYU Langone Hospital - Long Island, Mineola
и уште 7

Се регрутираФаза 2

Возраст од 1 до 30 · Сите полови · Ажурирано 1.9.2026 · NCT04546399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Albany Medical Center, Albany
Maimonides Medical Center, Brooklyn
Roswell Park Cancer Institute, Buffalo
и уште 12

Се регрутираФаза 3

365 Days – 25 Years · Сите полови · Ажурирано 25.8.2026 · NCT03959085

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

Research Site, New York

Се регрутираФаза 1/2

Возраст 12 и постари · Сите полови · Ажурирано 19.8.2026 · NCT06137118

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

New York Medical College, Valhalla

Се регрутираФаза 1/2

Возраст од 13 до 90 · Сите полови · Ажурирано 6.8.2026 · NCT06533579

Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma

New York Medical Center, Valhalla

Се регрутираФаза 1/2

Возраст од 12 до 70 · Сите полови · Ажурирано 15.4.2026 · NCT04491370

Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Memorial Sloan Kettering Cancer Center, New York

Се регрутираФаза 2

Возраст од 18 до 54 · Сите полови · Ажурирано 17.3.2026 · NCT06918431

Study of SGR-1505 in Mature B-Cell Neoplasms

Roswell Park Comprehensive Cancer Center, Buffalo
Weill Cornell, New York
Montefiore Medical Center, The Bronx

Се регрутираФаза 1

Возраст 18 и постари · Сите полови · Ажурирано 13.2.2026 · NCT05544019

ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML

Roswell Park Comprehensive Cancer Center, Buffalo

Се регрутираФаза 1

Возраст 18 и постари · Сите полови · Ажурирано 4.11.2025 · NCT03595917

Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

Roswell Park Comprehensive Cancer Center, Buffalo
Memorial Sloan Kettering Cancer Center (MSKCC) David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York

Се регрутираФаза 1/2

Возраст од 15 до 50 · Сите полови · Ажурирано 9.9.2025 · NCT04150497

Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL

New York Medical College, Valhalla

Се регрутираФаза 2

Возраст од 3 до 31 · Сите полови · Ажурирано 8.8.2025 · NCT02393157

The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL

Roswell Park Cancer Institute, Buffalo

Се регрутираФаза 2

Возраст од 1 до 25 · Сите полови · Ажурирано 4.5.2025 · NCT03509961

Од ClinicalTrials.gov, податоци преземени 5.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.